Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NIVOREN trial (nivolumab): what clinicians have said so far
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
- NCT03013335 ↗
- Completed
- UNICANCER
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on NIVOREN (nivolumab in metastatic clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NIVOREN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 14 posts on X, typically up to 62 once built | |
| 2 YouTube videos, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Nivolumab
- Arms
- Nivolumab · Experimental
- Enrollment
- 730
- Primary outcomes
- Incidence for high-grade (Grade3-4-5) adverse reactions of interest
- Sponsor
- UNICANCER with Bristol-Myers Squibb
- Start
- Jan 2016
- Primary completion
- Jun 2018
- Results posted
- No
- Registry record
- NCT03013335 · updated Oct 6, 2021
Publications
linked from the registry- Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. Clin Genitourin Cancer. 2022 Oct;20(5):488-494. doi: 10.1016/j.clgc.2022.07.003. Epub 2022 Jul 10. PubMed 35977881
- Billon E, Chanez B, Rochigneux P, Albiges L, Vicier C, Pignot G, Walz J, Chretien AS, Gravis G, Olive D. Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma. Front Immunol. 2021 Apr 20;12:670827. doi: 10.3389/fimmu.2021.670827. eCollection 2021. PubMed 33959132
- Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Negrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthelemy P, Narciso B, Houede N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13. PubMed 31194611